Current status of scientific classification: November 4, 2026.
Can olive oil affect tumor growth? A study published in the peer-reviewed journal Nutrients on August 23, 2026 investigated natural olive oil phenols in an experimental mouse model of triple-negative breast cancer. In one experimental group, the tumor burden was 46% lower at the end of the study than in the control group.
The short answer: This is an interesting result from preclinical research. It is not evidence that consuming olive oil prevents or treats cancer in humans.
Particularly relevant for Green Agora is the origin of the material studied: The producer PAMAKO from Crete provided the extra virgin olive oil for the research. Phenols were isolated from olive oil and concentrated into a standardized extract with 40% phenol content.
In this post, we explain the experimental design, the difference between the extract and olive oil, the role of PAMAKO, and the limitations of the scientific findings. We also contextualize the documented laboratory values of PAMAKO Gold and Silver separately from the tumor experiments.
What was published on August 23, 2026?
The original paper is titled Time-Dependent Multimechanistic Antitumor Effects of Olive Oil Phenolics in a Triple-Negative Breast Cancer Mouse Model. It appeared on August 23, 2026 in Nutrients, Volume 18, Issue 17, Article 2756. The DOI is 10.3390/nu18172756.
The study was conducted by scientists from the Hellenic Pasteur Institute, the National and Kapodistrian University of Athens, and the National Hellenic Research Foundation. The authors include Nikoleta Anna Madelou, Prokopios Magiatis, and Haralabia Boleti.
On October 30, 2026, journalist Lisa Radinovsky reported on the results in Greek Liquid Gold. Our assessment is based on the original scientific publication, not solely on subsequent reporting.
To the original study on PubMed and the full publication in Nutrients.
What does triple-negative breast cancer mean?
So-called triple-negative breast cancer, internationally known as Triple-Negative Breast Cancer or TNBC, is a particular form of breast cancer. The tumors studied do not possess the three receptor characteristics that are important for selecting certain established therapies.
For the animal experiment, the scientists used human breast cancer cells from the MDA-MB-231 cell line. These were implanted into immunocompromised mice. This allowed the researchers to compare the development of the tumors under controlled conditions.
This was expressly not a clinical study in humans with breast cancer. The experimental design allows for initial statements about biological mechanisms, but not immediate dietary recommendations for patients.
Results at a glance | 46%, 35%, and 29%
The study consisted of several experimental parts. The different figures must therefore always be assigned to their respective experimental group.
| Experimental condition | Result regarding tumor burden | Contextualization |
|---|---|---|
| Concentrated phenol extract, started 7 days before implantation | 46% lower | Statistically significant, p = 0.0008 |
| Concentrated phenol extract, started 5 days after implantation | 35% lower | Statistically significant, p = 0.0439 |
| Concentrated phenol extract, started 20 days after implantation | No proven inhibitory effect | No statistically significant difference |
| Directly administered phenol-rich olive oil, started 7 days before implantation | 29% lower | Not statistically significant, p = 0.178 |
The difference is crucial: The frequently cited figure of 46% comes from the experiment with a concentrated phenol extract. It does not describe the effect of a normal serving of PAMAKO olive oil.
In a separate experiment with phenol-rich olive oil, the tumor burden was indeed 29% lower than in mice that received dephenolated olive oil. However, due to the small sample size and the spread of the results, this difference was not statistically significant. It must not be presented as a proven effect.
The animal groups were small. Furthermore, the authors point out that the statistical results in sensitivity analyses were influenced by the treatment of outlier measurements. Further independent studies with larger groups are therefore necessary.
Why did the timing of administration play such a big role?
In the strongest result, the administration of the phenolic mixture began as early as seven days before the implantation of the human cancer cells. The animals subsequently received the extract three times a week; the tumors were evaluated 40 days after implantation.
When the treatment was started only five days after implantation, the tumor burden was also lower. In contrast, starting on day 20 showed no detectable inhibitory effect.
For science, this timing pattern is interesting. The authors discuss a possible effect in the very early stages of tumor development. However, the term used in the laboratory for a possible preventive effect refers to this experimental model.
For healthy people, no recommendation for cancer prevention through olive oil or phenol preparations can be derived from this.
Phenol extract is not the same as a bottle of olive oil
The scientists isolated natural phenolic compounds from the olive oil provided by PAMAKO. The isolated material was adjusted in a special formulation to a total phenol content of 40% by weight.
The oral phenol dose in the described experiment was 5 mg of total phenols per kilogram of mouse body weight. Administration was carried out under laboratory conditions via a tube, not as part of a regular meal.
The 40% refers to the extract, not to the phenol content of the bottled culinary olive oil. Furthermore, animal doses cannot simply be converted to human tablespoons or serving sizes.
In the additional oil experiment, the animals received directly phenol-rich extra virgin olive oil and, for comparison, an oil produced from the same batch of oil that was largely free of the studied phenols. Precisely because the scientists tested these variants separately, we should also consider them separately in our reporting.
What role did PAMAKO from Crete play?
The original study explicitly documents that the extra virgin olive oil used was provided by the producers of PAMAKO. The phenols further processed in the laboratory thus had a concrete origin.
For Green Agora, this is relevant producer information: An olive oil from our range does not only stand for origin, varieties, and sensory characteristics. It was also used as the starting material for a scientific research paper.
However, the study is not a clinical efficacy test of PAMAKO Gold or Silver as commercially available food products. It allows neither a therapeutic statement about the bottles nor a ranking by cancer prevention effect.
Anyone who would like to get to know PAMAKO as a food product more closely will find detailed information about Tsounati, Blend, origin, and analysis in our existing guide: PAMAKO Gold and Silver | Origin, Laboratory Values, and Quality.
PAMAKO Gold and Silver | The documented laboratory values of the 2025/26 harvest
At Green Agora, we always consider laboratory values together with the studied sample. For the November 2025 harvest, two analyses are available in the existing PAMAKO technical article. Both were conducted on November 21, 2025; the certificates were issued on November 25, 2025.
| Analyzed Parameter | PAMAKO Gold Monovarietal | PAMAKO Silver Blend |
|---|---|---|
| Certificate | C2526 00362 | C2526 00363 |
| Analyzed Total Phenols | 2,081 mg/kg | 1,466 mg/kg |
| Oleocanthal | 1,318 mg/kg | 758 mg/kg |
| Oleacein | 264 mg/kg | 187 mg/kg |
| Derivatives listed in the certificate per 20 g | 41.62 mg | 29.33 mg |
These values apply to the specific samples analyzed. They do not automatically describe every earlier or future harvest, every batch, or every product set.
Gold is a pure Tsounati olive oil, while Silver combines Tsounati with Koroneiki. Different variety compositions and phenol profiles allow for an interesting comparison. A higher measured value does not automatically mean that an olive oil is the better choice for every taste.
Another important difference: The laboratory values from November 2025 are not the analytical data of the tumor experiments published in August 2026. Neither the exact composition of the extract used at that time nor its result can be derived from them or transferred to a current sales bottle.
We explain the analysis documents and the exact contextualization in the PAMAKO Laboratory Values Guide.
Which natural compounds did the scientists study?
The substances studied included oleocanthal, oleacein, oleuropein aglycone, ligstroside aglycone, hydroxytyrosol, and tyrosol. The researchers tested isolated compounds and mixtures as well as a total phenol extract.
In the laboratory, changes were observed in protein oxidation, proteasome activity – a cellular system for breaking down proteins – and markers associated with DNA damage. In cell culture experiments, the phenolic mixture also influenced the mobility of cancer cells.
Such biological observations help to investigate possible mechanisms of action. However, they are not evidence of successful cancer treatment in the human body.
If you would like to deepen your understanding of the basics of this group of substances: Understanding Polyphenols in Olive Oil.
What does the study say about oleocanthal alone?
In another part of the experiment, isolated oleocanthal was injected into the abdominal cavity of mice. Here, the tumor weight was 33.1% lower than the control group at the end of the study; this difference was statistically significant in the described experiment (p = 0.0197).
However, the group consisted of only four mice. Furthermore, an intraperitoneal injection is no comparison to the consumption of extra virgin olive oils.
The results highlight the research interest in oleocanthal, not the clinical efficacy of a specific culinary oil.
More background can be found in our post Oleocanthal | Ingredient, Pungency, and Research.
What does the EU Health Claim about olive oil polyphenols mean?
In the European Union, there is an approved health claim: Olive oil polyphenols contribute to the protection of blood lipids from oxidative stress.
This claim may only be used under certain conditions. These include at least 5 mg of hydroxytyrosol and its derivatives per 20 g of olive oil, as well as the indication that the positive effect occurs with a daily intake of 20 g of olive oil.
This is a clearly defined statement about the protection of blood lipids from oxidative stress – no approval of a statement on cancer prevention.
More on this: Correctly Understanding EU Health Claims for Olive Oil.
Getting to know PAMAKO Gold and Silver as food products
For the scientific classification of this study, it is crucial to distinguish between a specially produced research extract and the olive oils available on the market. PAMAKO Gold Monovarietal and PAMAKO Silver Blend are food products for the kitchen and enjoyment, not products for cancer prevention or cancer treatment.
Anyone who would like to compare both olive oils independently of the medical research topic can explore their origin, the Tsounati olive variety, the combination with Koroneiki in the Silver Blend, and their respective sensory characteristics. Our existing analyses help to contextualize the specific samples studied.
We explain these culinary and analytical differences in detail in the Green Agora Guide to PAMAKO Gold, Silver, Origin, and Laboratory Values. There, readers will also find guidance on the available product variants.
Ayhan's personal assessment | What interests me about this research
At Green Agora, I deal with olive oil as a high-quality food product. I am interested in the people behind the production, the olive varieties, the sensory quality, and the results of verifiable analyses.
The study makes it clear to me why it is worth paying close attention to research on natural olive oil components.
The fact that PAMAKO provided the starting material is a remarkable connection between an olive oil producer and basic scientific research.
What I do not make from this is a health promise for a bottle of olive oil. I can explain the origin, the analysis, and the taste of PAMAKO. Whether a concentrated phenol extract will one day gain medical significance must be clarified by researchers and clinical studies.
Analysis without a human remains a number. Experience without analysis remains an observation.
Ayhan from Green Agora
Further information on our selection philosophy: Get to know Ayhan and Green Agora.
Conclusion | An important study, but not evidence of cancer prevention through olive oil
The work published on August 23, 2026 shows interesting effects of olive oil phenols in an experimental mouse model of triple-negative breast cancer.
The strongest reported difference was 46% lower tumor burden when a concentrated phenol extract was administered before the implantation of the cancer cells. In contrast, the direct administration of phenol-rich olive oil resulted in a not statistically significant reduction of tumor burden by 29%.
The fact that the starting oil came from PAMAKO in Crete is documented and interesting producer information. However, it does not prove a preventive or therapeutic effect of the PAMAKO products offered by Green Agora.
Good olive oil deserves attention for its verifiable qualities – and science deserves an accurate presentation of its results and limitations.
Frequently Asked Questions about the 2026 Olive Oil Study
When was the study published?
On August 23, 2026, in the peer-reviewed journal Nutrients. On October 30, 2026, a journalistic report by Lisa Radinovsky was published in addition.
Did tumors in mice become 46% smaller?
At the end of the experiment, a 46% lower total tumor burden was measured compared to the control group. This is not equivalent to a 46% reduction in cancer risk in humans.
Was regular PAMAKO olive oil administered in the experiment?
In the experiments leading to the 46% result, a concentrated phenol extract was used. A separate experiment investigated directly administered phenol-rich olive oil.
What was the result with directly administered olive oil?
The tumor burden was 29% lower in this experimental arm. The difference was not statistically significant and therefore only considered preliminary evidence.
Where did the olive oil for the extract come from?
The authors cite the producers of PAMAKO as the supplier of the studied olive oil in the original study.
What does the phenol content of 40% mean?
It describes the specially produced concentrated research extract, not the phenol content of the sold olive oil bottles.
What distinguishes PAMAKO Gold from Silver?
Gold is pure Tsounati olive oil. Silver is a blend of Tsounati and Koroneiki. The documented analyses also differ and are always attributable to a specific sample.
Can PAMAKO olive oil prevent or treat cancer?
This has not been proven. The animal study cannot be directly extrapolated to humans or commercially available consumption amounts.
Is there an EU-approved health claim for olive oil?
Yes, subject to statutory conditions, for protecting blood lipids from oxidative stress. There is no approved claim for cancer prevention for olive oil.
Scientific sources and further information
- Madelou et al. (23.08.2026) | Time-Dependent Multimechanistic Antitumor Effects of Olive Oil Phenolics in a Triple-Negative Breast Cancer Mouse Model | Nutrients 18(17), 2756 | DOI 10.3390/nu18172756
- PubMed | PMID 42738930 | Abstract and publication data
- Lisa Radinovsky (30.10.2026) | Olive Oil in Cancer Prevention: Tumors Down by 46% in Mice | Greek Liquid Gold
- Regulation (EU) No 432/2012 | Conditions of the approved claim for olive oil polyphenols
- Green Agora | PAMAKO Gold and Silver | Analyses of the 2025/26 harvest
The information on the tumor experiments comes from the original publication, not from a study on humans. The PAMAKO products mentioned are presented as food.
